Skip to content
Sunday, November 8, 2026
Modern Vault Agency

Users Discontinuing Slimming Injections Regain Pounds Four Times Faster Compared to People Using Diet and Exercise

Illustration of pharmaceutical injection and scale
Obesity treatment involves long-term strategies.

New research indicates that patients who come off blockbuster weight-loss injections like semaglutide or tirzepatide can put back on lost weight far faster than those who stop conventional lifestyle plans.

Research printed in a major medical journal shows that while obese people often shed substantial amounts of their body weight while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month after stopping.

"Individuals purchasing such treatments need to be cognizant of the risk of quick weight regain when the medication ends," warns researcher Dr. Susan Jebb.

That rate of regain implies a return to pre-treatment mass in about one and a half years.

Weighing Therapies

The research, which reviewed dozens of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with other pills.

Scientists emphasize that individuals who lose weight through dieting typically see a slower creep back—approximately 100 grams monthly—once they finish.

The Reason for the Fast Rebound

Experts suggest the mechanism of the jabs explains the accelerated rebound.

GLP-1 drugs imitate a body's own chemical called GLP-1, which controls hunger.

"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.

"Stopping of this GLP-1 'fix' means appetite is uncontrolled, making binge eating much more probable."

A Chronic Issue?

The NHS suggest the jabs for people with weight-linked health risks, alongside recommended lifestyle changes.

Many experts say that, considering the high risk of relapse, the therapy might need to be life-long.

This perspective is reinforced by pharmaceutical companies, who say that the results "highlight the persistent nature of obesity," comparing it to managing diseases like hypertension.

User Experiences

Users who have discontinued the jabs explain a sudden return of appetite.

"It was like a trigger that goes on and I was suddenly starving," described one woman.

The struggle is exacerbated if patients have not established lasting dietary or behavioural modifications during therapy.

Widespread Interest

Survey data indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.

  • Adoption is greater among females than males.
  • The middle-aged age group shows the greatest usage rates.
  • Many access the medications through private healthcare rather than the NHS.

In conclusion, clinicians caution that while GLP-1 drugs are effective tools for weight loss, they are not a standalone solution and maintained weight loss hinges on integrated behavioural changes.

JW
About the author

Jessica Walker

Elena Whitfield is a cybersecurity expert and digital legacy consultant with over a decade of experience in data protection.

Modern Vault Agency

Type to search articles.